Biogen Idec 2010 total revenues boost 8 percent to $4.7 billion Biogen Idec Inc cialis quotidien prix http://tadalafil-en-belgique.com . , a worldwide biotechnology head in the discovery, advancement, production, and commercialization of innovative treatments, announced its full calendar year and fourth quarter 2010 results today.7 billion, a rise of 8 percent versus 2009.5 billion.1 billion for the year due to the expiration of royalties on product sales outside the United Claims. Global in-marketplace 2010 TYSABRI net product sales had been $1.2 billion, a rise of 16 percent over 2009.